A new study suggests that microorganisms discovered on Dokdo could provide new insights for treating intractable brain diseases such as dementia and Parkinson's disease.


The Korea Research Institute of Bioscience and Biotechnology (KRIBB) announced on March 9 that a research team led by Dr. Jae-Hyuk Jang and Dr. Junpil Jang at the Chemical Biology Research Center, together with Dr. Kyungsu Kang's team at the Natural Product Systems Biology Research Center of the Korea Institute of Science and Technology (KIST), have identified a new compound called "Dokdothiocin" from microorganisms found in Dokdo soil, which can reduce brain inflammation.


(From left) Dr. Jaehyuk Jang and Dr. Junpil Jang from the Korea Research Institute of Bioscience and Biotechnology, Dr. Kyungsu Kang from KIST. Korea Research Institute of Bioscience and Biotechnology

(From left) Dr. Jaehyuk Jang and Dr. Junpil Jang from the Korea Research Institute of Bioscience and Biotechnology, Dr. Kyungsu Kang from KIST. Korea Research Institute of Bioscience and Biotechnology

View original image

Dokdothiocin is a new compound derived from a previously discovered microorganism on Dokdo, "Streptomyces sp. 20A130."


Streptomyces is known for its ability to produce various medicinal substances, including antibiotics, and has emerged as an important microorganism in the search for new drug candidates.


The joint research team discovered Dokdothiocin, a previously unreported compound, by diversifying the cultivation environment of Streptomyces so that it could produce new substances not typically generated. They succeeded in isolating and purifying this compound.


Dokdothiocin has a highly unique structure, with 29 atoms connected in a ring formation. The research team emphasized that the structural rarity of this compound gives it high potential as a next-generation drug candidate that could overcome the limitations of existing therapies.


To verify whether the novel structure of Dokdothiocin is effective against neuroinflammation, the team conducted a convergence study combining artificial intelligence (AI) and cell experiments. The results scientifically demonstrated the therapeutic potential of the compound.


In experiments, KIST used its proprietary "protein target prediction AI technology" to predict that Dokdothiocin could block key pathways that regulate inflammatory signaling in the brain.


Furthermore, actual cell experiments confirmed that Dokdothiocin significantly alleviated the inflammatory response in brain immune cells induced by inflammation and effectively inhibited the production of harmful substances that cause cell damage. The AI's precise predictions were consistent with the experimental results.


This achievement is recognized as a joint research outcome in which KRIBB discovered a new substance from Dokdo microorganisms and elucidated the biosynthetic mechanism, while KIST scientifically demonstrated the compound's efficacy and mechanism of action in relation to brain diseases.


The significance lies in the fact that the two institutions organically collaborated, not only discovering a novel compound but also identifying its mechanism of action, thereby developing it into a drug candidate.


Dr. Jae-Hyuk Jang of KRIBB stated, "This study scientifically proves the potential of microorganisms in Dokdo soil," and added, "KRIBB will continue to contribute to increasing the efficiency of drug development through integration with AI technologies."


Dr. Kyungsu Kang of KIST emphasized, "By using AI-based protein target prediction technology, we were able to quickly identify the potential mechanisms of Dokdothiocin," and added, "This achievement presents a new research model that combines the discovery of new compounds with AI technology."



Meanwhile, the results of this research (paper) were published online in the international chemistry journal 'Organic Letters' on February 27.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing